Atomoxetine tablets 25 mg for attention-deficit/hyperactivity disorder (ADHD, Strattera)

What are Atomoxetine tablets 25 mg for the treatment of attention-deficit/hyperactivity disorder (ADHD, Strattera)?

Atomoxetine tablets present a focused strategy for addressing the symptoms of attention-deficit/hyperactivity disorder (ADHD), offering relief to individuals contending with issues of inattention, hyperactivity, or impulsiveness. As a pivotal component in ADHD therapy, these tablets operate by regulating neurotransmitters responsible for transmitting information between nerve cells in the brain. This mode of action is pivotal in tackling the fundamental symptoms linked with ADHD, thereby rendering atomoxetine tablets an invaluable choice for those requiring efficient symptom management.

A noteworthy advantage of atomoxetine tablets lies in their suitability across a wide age spectrum. Whether for adults grappling with ADHD or children as young as 6 years old, these tablets present a versatile therapeutic option that caters to diverse needs across different age brackets. This versatility not only enhances accessibility but also ensures that individuals of varying ages can derive benefits from effective ADHD management.

Furthermore, the efficacy of atomoxetine tablets is substantiated by extensive research and clinical trials. Multiple studies have confirmed the effectiveness of the active ingredients in mitigating ADHD symptoms, emphasizing the reliability of this treatment avenue. For instance, in a comprehensive study titled "Safety and Tolerability of Atomoxetine Hydrochloride in a Long-Term, Placebo-Controlled Randomized Withdrawal Study in European and Non-European Adults with Attention-Deficit/Hyperactivity Disorder," researchers observed positive outcomes in over 2000 patients spanning 18 countries. The study showcased that atomoxetine exhibited a satisfactory safety profile in adults with ADHD, with sustained efficacy even after 1 year of treatment. Importantly, no clinically significant safety-related rebound effects were detected following abrupt discontinuation after 24 weeks of treatment, further reinforcing the favorable risk-benefit profile of atomoxetine tablets.

In summary, atomoxetine tablets offer a dependable and efficient solution for individuals seeking to manage ADHD symptoms. With their capacity to target core symptoms and their demonstrated efficacy across diverse age groups, these tablets provide a comprehensive approach for those navigating the complexities of ADHD. Supported by robust research evidence, atomoxetine tablets stand as a cornerstone in ADHD treatment, offering hope and relief to countless individuals worldwide.

Active principles: atomoxetine hydrochloride

Amount: 140 tablets

Indications: attention-deficit/hyperactivity disorder (ADHD)

How to take:

For patients under 18 years old: start this medication at a daily total of 0.5 mg/kg as atomoxetine, then increase to 0.8 mg/kg daily, and subsequently up to 1.2 mg/kg. Maintenance should fall within the range of 1.2 to 1.8 mg/kg per day. Adjustments should occur weekly or longer. In all cases, the medicine should be taken in 2 separate doses daily. Dosage may be tailored based on symptoms, but should not exceed 1.8 mg/kg or 120 mg daily, whichever is lower.

For patients 18 years or older: begin with a total daily dose of 40 mg as atomoxetine, increasing to 80 mg daily, with maintenance ranging from 80 to 120 mg daily. Up to 80 mg, increments should happen weekly or longer, then at intervals of 2 weeks or longer beyond 80 mg. Administer as a single daily dose or divided into two. Dosage adjustments can be made based on symptoms, but should not exceed 120 mg per day.

Each preparation contains 25 mg of atomoxetine. Do not crush or grind the tablet; swallow whole to avoid eye irritation. If particles come into contact with your eyes, rinse with water immediately and seek medical advice. If particles touch your skin, wash thoroughly with water.

Contraindications and precautions: The medication could induce drowsiness or dizziness. Refrain from driving or operating hazardous machinery following its administration. Do not expose to sunlight or heat. If allergic symptoms occur, discontinue use. Do not use in the following cases:

• pregnant or breastfeeding,
• cardiovascular disorder, 
• pheochromocytoma or a history of it, 
• angle-closure glaucoma.